Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Biological systems are notoriously tough to model, especially when it comes to figuring out the axons, neurons, blood vessels, and other structural components of gray matter, or the tissue that makes ...

WASHINGTON — Array Labs, a Silicon Valley startup developing radar-based Earth observation satellites, announced Jan. 5 it raised $20 million in a Series A round as it pushes to bring lower-cost ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 7 minutes ...

In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the University of Cambridge. The lecture was called "Is the end in sight for theoretical physics?" Forty-five years later, ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

NEW YORK - September 9, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks ...

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune misled investors about the prospects of its IGNYTE trial for RP1 (vusolimogene ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune ...